4//SEC Filing
Fleming Alison B 4
Accession 0001192482-21-000211
CIK 0001267565other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 8:01 PM ET
Size
30.7 KB
Accession
0001192482-21-000211
Insider Transaction Report
Form 4
Fleming Alison B
Vice President, Product Devlp
Transactions
- Sale
Common Stock
2018-01-12$21.00/sh−1,747$36,687→ 156,164 total - Sale
Common Stock
2018-01-12$21.00/sh−5,753$120,813→ 156,164 total - Exercise/Conversion
Common Stock
2018-01-19$0.90/sh+64$58→ 156,228 total - Sale
Common Stock
2018-01-19$23.00/sh−64$1,472→ 156,164 total - Sale
Common Stock
2018-01-19$23.00/sh−1,811$41,653→ 156,164 total - Sale
Common Stock
2018-05-10$27.00/sh−1,400$37,800→ 154,764 total - Exercise/Conversion
Stock Option (Right to Purchase)
2018-01-12−1,747→ 64 totalExercise: $0.90Exp: 2019-04-23→ Common Stock (1,747 underlying) - Exercise/Conversion
Stock Option (Right to Purchase)
2018-01-12−5,753→ 0 totalExercise: $0.48Exp: 2023-01-24→ Common Stock (5,753 underlying) - Exercise/Conversion
Stock Option (Right to Purchase)
2018-01-19−1,449→ 0 totalExercise: $3.31Exp: 2021-02-08→ Common Stock (1,449 underlying) - Exercise/Conversion
Common Stock
2018-01-12$0.48/sh+5,753$2,761→ 161,917 total - Exercise/Conversion
Common Stock
2018-01-19$0.90/sh+1,811$1,630→ 157,975 total - Sale
Common Stock
2021-03-01$23.36/sh−6,011$140,417→ 148,753 total - Exercise/Conversion
Stock Option (Right to Purchase)
2018-01-19−64→ 0 totalExercise: $0.90Exp: 2019-04-23→ Common Stock (64 underlying) - Exercise/Conversion
Common Stock
2018-01-12$0.90/sh+1,747$1,572→ 157,911 total - Exercise/Conversion
Common Stock
2018-01-19$3.31/sh+1,449$4,796→ 157,613 total - Sale
Common Stock
2018-01-19$23.00/sh−1,449$33,327→ 156,164 total - Exercise/Conversion
Stock Option (Right to Purchase)
2018-01-19−1,811→ 0 totalExercise: $0.90Exp: 2020-02-26→ Common Stock (1,811 underlying)
Footnotes (6)
- [F1]Certain transactions reported in this Form 4 are late due to an administrative error.
- [F2]The sales reported in these rows were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017.
- [F3]The sale reported in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2018.
- [F4]The sale reported in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2020.
- [F5]The option was fully vested and exercisable as of January 12, 2018.
- [F6]The option was fully vested and exercisable as of January 19, 2018.
Documents
Issuer
COLLEGIUM PHARMACEUTICAL, INC
CIK 0001267565
Entity typeother
Related Parties
1- filerCIK 0001640701
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 8:01 PM ET
- Size
- 30.7 KB